Alexandria Hammond
Stock Analyst at B of A Securities
(3.37)
# 1,014
Out of 5,005 analysts
17
Total ratings
58.33%
Success rate
5.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETNB 89bio | Maintains: Buy | $30 → $29 | $14.85 | +95.29% | 2 | Aug 25, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $46.10 | +38.83% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $600.00 | +91.67% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $27.37 | -8.66% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $28.49 | +40.40% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $89.19 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $839.87 | +19.07% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $188.64 | +0.72% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $112.69 | -2.39% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $45.45 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $159.88 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $233.91 | -12.36% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $443.01 | -66.14% | 1 | Apr 22, 2024 |
89bio
Aug 25, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $14.85
Upside: +95.29%
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $46.10
Upside: +38.83%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $600.00
Upside: +91.67%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $27.37
Upside: -8.66%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $28.49
Upside: +40.40%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $89.19
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $839.87
Upside: +19.07%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $188.64
Upside: +0.72%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $112.69
Upside: -2.39%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $45.45
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $159.88
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $233.91
Upside: -12.36%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $443.01
Upside: -66.14%